Results 31 to 40 of about 24,401 (257)

Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL [PDF]

Current Opinion in Lipidology, 2015
Randomized clinical trials provide strong evidence that pharmacological elevation of HDL-cholesterol (HDL-C) fails to reduce cardiovascular disease (CVD) risk in statin-treated humans. It is thus critical to identify new metrics that capture HDL's cardioprotective effects.We review recent evidence that HDL's cholesterol efflux capacity is a strong ...
Patrick M, Hutchins, Jay W, Heinecke
openaire   +2 more sources

Cholesterol Efflux Capacity, Carotid Atherosclerosis, and Cerebrovascular Symptomatology [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2014
Objective— To investigate the association of cholesterol efflux capacity with carotid atherosclerosis and cerebrovascular disease. Approach and Results— Patients with high-grade carotid stenosis (n=154) were recruited from Vascular Surgery clinics and 9 healthy ...
R J, Doonan, A, Hafiane, C, Lai, J P, Veinot, J, Genest, S S, Daskalopoulou   +5 more
openaire   +2 more sources

Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway[S]

Journal of Lipid Research, 2016
Cholesterol efflux capacity associates strongly and negatively with the incidence and prevalence of human CVD. We investigated the relationships of HDL's size and protein cargo with its cholesterol efflux capacity using APOB-depleted serum and HDLs ...
Nathalie Pamir, Patrick Hutchins, Graziella Ronsein, Tomas Vaisar, Catherine A. Reardon, Godfrey S. Getz, Aldons J. Lusis, Jay W. Heinecke   +7 more
doaj   +1 more source

ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundAnimal and human studies indicate that ABCA1‐mediated cholesterol transport is important in Alzheimer's disease (AD). We hypothesized that the efficiency of cerebrospinal fluid (CSF) to facilitate ABCA1‐mediated cholesterol efflux would be ...
Hussein N. Yassine, Qingru Feng, Jiarong Chiang, Larissa M. Petrosspour, Alfred N. Fonteh, Helena C. Chui, Michael G. Harrington   +6 more
doaj   +1 more source

Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART[S]

Journal of Lipid Research, 2015
The capacity of HDL to remove cholesterol from macrophages is inversely associated with the severity of angiographic coronary artery disease. The effect of human immunodeficiency virus (HIV) infection or its treatment on the ability of HDL particles to ...
Petra El Khoury, Mathilde Ghislain, Elise F. Villard, Wilfried Le Goff, Caroline Lascoux-Combe, Patrick Yeni, Laurence Meyer, Corinne Vigouroux, Cécile Goujard, Maryse Guerin   +9 more
doaj   +1 more source

Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport

Journal of Lipid Research, 2017
Phospholipid transfer protein (PLTP) may affect macrophage reverse cholesterol transport (mRCT) through its role in the metabolism of HDL. Ex vivo cholesterol efflux capacity and in vivo mRCT were assessed in PLTP deletion and PLTP overexpression mice ...
Takashi Kuwano, Xin Bi, Eleonora Cipollari, Tomoyuki Yasuda, William R. Lagor, Hannah J. Szapary, Junichiro Tohyama, John S. Millar, Jeffrey T. Billheimer, Nicholas N. Lyssenko, Daniel J. Rader   +10 more
doaj   +1 more source

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. [PDF]

J Am Heart Assoc, 2023
europepmc   +4 more sources

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. [PDF]

J Am Heart Assoc, 2020
Background Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport, is inversely associated with
Metzinger MP, Saldanha S, Gulati J, Patel KV, El-Ghazali A, Deodhar S, Joshi PH, Ayers C, Rohatgi A.   +8 more
europepmc   +5 more sources

Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol transport. [PDF]

PLoS ONE, 2017
This study was aimed to investigate the effect of human PON1 overexpression in mice on cholesterol efflux and reverse cholesterol transport.
Souade Ikhlef, Hicham Berrougui, Olivier Kamtchueng Simo, Echarki Zerif, Abdelouahed Khalil   +4 more
doaj   +1 more source

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis. [PDF]

Arthritis Res Ther, 2021
Abstract Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events.
Ferraz-Amaro I, Delgado-Frías E, Hernández-Hernández V, Sánchez-Pérez H, de Armas-Rillo L, Armas-González E, Machado JD, Diaz-González F.   +7 more
europepmc   +8 more sources